Effectiveness of carbonic anhydrase inhibitor loaded nanoparticles in the treatment of diabetic retinopathy

Creative Commons License

UĞURLU N., ERDAL E., Malekghasemi S., Demirbilek M.

Biomedical physics & engineering express, vol.10, no.1, 2023 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 10 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1088/2057-1976/acba9d
  • Journal Name: Biomedical physics & engineering express
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Compendex, EMBASE, INSPEC, MEDLINE
  • Keywords: acetazolamide, carbonic anhydrase inhibitor, diabetic retinopathy, nanoparticles, poly(3-hydroxybutyrate-co-3-hydroxyvalerate)
  • Hacettepe University Affiliated: Yes


Diabetic Retinopathy (DRP) is a disease consisting of all the structural and functional changes that develop in the retinal layer of the eye due to diabetes. DRP is the most important cause of blindness between the ages of 20-74 in the world, and the most successful standard treatment option in the treatment of DRP is intravitreal injections. To synthesize acetazolamide loaded nanoparticles to be applied intravitreal treatment of DRP and to examine thein vitroefficacy of the nanoparticles. ACZ loaded PHBV nanoparticles (PHBV-ACZ NPs) formulations were prepared. Nanoparticles with a particle size of 253.20 ± 0.55 nm. A DRP model was established and characterized in HRMEC cells. The effect of the nanoparticles on permeability has been investigated and carrier proteins in BRB due to the development of DRP has been investigated. To establish thein vitroDRP model, HRMEC was stimulated with Recombinant human 165 Vascular Endothelial Growth Factor (VEGF), thereby temporarily reducing the expression levels of endothelial junction proteins, increasing the number of intercellular spaces in the monolayers of HRMECs. It was determined that after the cells were exposed to Carbonic anhydrase inhibitors (CAI) loaded nanoparticles, permeability decreased and protein expression increased.